Table Graph
      published meta-analysis   sensitivity analysis   studies

proxalutamide in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCadegiani, 2021 0.22 [0.16; 0.31] 0.22[0.16; 0.31]Cadegiani, 202110%645NAnot evaluable deathsdetailed resultsCadegiani, 2021 0.16 [0.11; 0.24] 0.16[0.11; 0.24]Cadegiani, 202110%645NAnot evaluable deaths (time to event analysis only)detailed resultsCadegiani, 2021 0.16 [0.11; 0.24] 0.16[0.11; 0.24]Cadegiani, 202110%645NAnot evaluable clinical improvementdetailed resultsCadegiani, 2021 2.28 [1.95; 2.66] 2.28[1.95; 2.66]Cadegiani, 202110%645NAnot evaluable clinical improvement (14-day)detailed resultsCadegiani, 2021 2.28 [1.95; 2.66] 2.28[1.95; 2.66]Cadegiani, 202110%645NAnot evaluable clinical improvement (28-day)detailed resultsCadegiani, 2021 1.81 [1.60; 2.05] 1.81[1.60; 2.05]Cadegiani, 202110%645NAnot evaluable mechanical ventilationdetailed resultsCadegiani, 2021 0.10 [0.04; 0.29] 0.10[0.04; 0.29]Cadegiani, 202110%645NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-28 21:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 819 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons